SCHEMBL3353782

SCHEMBL3353782

O=[N+]([O-])c1ccc2ccn(C3CCNCC3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
SLC6A4 P31645 1/20 0.42
CYP2C19 P33261 1/20 0.42
THPO P40225 1/20 0.42
HTR3A P46098 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42
CDC7 O00311 1/20 0.41
HTR7 P34969 1/20 0.40
ADRB1 P08588 1/20 0.39
SIRT6 Q8N6T7 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
ADRA2A P08913 1/20 0.38
PNMT P11086 1/20 0.38
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3354763 0.89 HTR3E (0.42) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL3353526 0.84 CDC7 (0.43) ALDH1A1CYP1A2CYP3A4CDC7HTR7
SCHEMBL3357611 0.84 CDC7 (0.43) ALDH1A1CYP1A2CYP3A4CDC7HTR7
SCHEMBL3359093 0.84 ALDH1A1 (0.41) ALDH1A1CDC7HTR7SIRT2
SCHEMBL3353280 0.83 HTR7 (0.53) SLC6A4CDC7HTR7SIRT6
SCHEMBL3353152 0.81 IRAK4 (0.44) ALDH1A1CYP1A2SLC6A4CDC7HTR7
SCHEMBL3352705 0.81 IRAK4 (0.44) ALDH1A1CYP1A2SLC6A4CDC7HTR7
SCHEMBL3357757 0.81 NPC1 (0.47) ALDH1A1CYP1A2CDC7HTR7SIRT2
SCHEMBL3352450 0.80 HTR7 (0.45) CYP1A2CDC7HTR7
SCHEMBL3352455 0.80 HTR7 (0.45) CYP1A2CDC7HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2141163-A1 Substituted thiazolidinones, their production and utilisation as medicine Bayer Schering Pharma AG (DE) 2010-01-06 EP disclosed
US-7071201-B2 Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline EISAI CO., LTD. (JP) 2006-07-04 US disclosed
EP-0976732-B1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES EISAI CO LTD (JP) 2004-11-24 EP disclosed
US-6579881-B2 Indoles EISAI CO., LTD. (JP) 2003-06-17 US disclosed
US-6448243-B1 SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA EISAI CO., LTD. (JP) 2002-09-10 US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 US disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019531-A1 Indoles INMT, MUSK, MB ALDH1A1 3599/4885HTR3E 231/4885HTR3B 155/4885
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 ALDH1A1 3941/4885HTR3E 204/4885HTR3B 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.